Tissue Regenix (UK) Top Management

TRX Stock   58.50  1.50  2.50%   
Tissue Regenix employs about 82 people. The company is managed by 6 executives with a total tenure of roughly 192 years, averaging almost 32.0 years of service per executive, having 13.67 employees per reported executive. Evaluation of Tissue Regenix's management performance can provide insight into the firm performance.
Daniel Lee  CEO
CEO Director
Tina Trimble  President
Donor President
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tissue Regenix Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Tissue Regenix Management Team Effectiveness

At present, Tissue Regenix's Other Current Assets are projected to increase significantly based on the last few years of reporting. Tissue Regenix's management efficiency ratios could be used to measure how well Tissue Regenix manages its routine affairs as well as how well it operates its assets and liabilities.
As of January 5, 2025, Common Stock Shares Outstanding is expected to decline to about 80.5 M. In addition to that, Net Loss is expected to decline to about (3.3 M)

Tissue Regenix Workforce Comparison

Tissue Regenix Group is currently regarded as top stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 21,097. Tissue Regenix adds roughly 82.0 in number of employees claiming only tiny portion of equities under Health Care industry.
The company has Profit Margin (PM) of (0.03) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.03 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.03.

Tissue Regenix Group Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Tissue Regenix Group Price Series Summation is a cross summation of Tissue Regenix price series and its benchmark/peer.

Tissue Regenix Notable Stakeholders

A Tissue Regenix stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Tissue Regenix often face trade-offs trying to please all of them. Tissue Regenix's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Tissue Regenix's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Daniel LeeCEO DirectorProfile
Tina TrimbleDonor PresidentProfile
Christine RowleyTechnical DirectorProfile
David CockeCFO DirectorProfile
Pr InghamConsultantProfile
Kirsten LundEMEA SecretaryProfile

About Tissue Regenix Management Performance

The success or failure of an entity such as Tissue Regenix Group often depends on how effective the management is. Tissue Regenix management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Tissue management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Tissue management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Tissue Regenix is entity of United Kingdom. It is traded as Stock on LSE exchange.
Please note, the presentation of Tissue Regenix's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tissue Regenix's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Tissue Regenix's management manipulating its earnings.

Tissue Regenix Workforce Analysis

Traditionally, organizations such as Tissue Regenix use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Tissue Regenix within its industry.

Tissue Regenix Manpower Efficiency

Return on Tissue Regenix Manpower

Revenue Per Employee359.7K
Revenue Per Executive4.9M
Net Loss Per Employee20.4K
Net Loss Per Executive278.2K
Working Capital Per Employee175.1K
Working Capital Per Executive2.4M

Complementary Tools for Tissue Stock analysis

When running Tissue Regenix's price analysis, check to measure Tissue Regenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tissue Regenix is operating at the current time. Most of Tissue Regenix's value examination focuses on studying past and present price action to predict the probability of Tissue Regenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tissue Regenix's price. Additionally, you may evaluate how the addition of Tissue Regenix to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Bonds Directory
Find actively traded corporate debentures issued by US companies
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.